Exponent is a specialized engineering and scientific consulting firm serving safety-critical problems for multinational corporations, law firms, insurers and government clients. It operates across approximately thirty offices and derives about 85% of net revenue from Engineering and Other Scientific work, with the balance from Environmental and Health services. Its more than 650 PhD-level professionals, ninety technical disciplines, scientific objectivity and specialized testing infrastructure create a differentiated position versus generalist consultants. **The financial trajectory remains strong:** Q1 FY2026 total revenue rose 14.3% to $166.303 million, net revenue increased 10.5% to $151.817 million, and diluted EPS grew 13.5% to $0.59, beating consensus of $0.57. Full-year guidance calls for high-single-digit net-revenue growth and a 27.6%–28.1% EBITDA margin. The long-term catalyst is proactive consulting tied to AI-integrated products, grid modernization and electrified transportation. However, valuation is demanding at a 31.8x forward P/E, prompting UBS and JP Morgan to reduce targets to $75 and $80. The report views Exponent as a high-quality long-term compounder, but near-term upside is constrained by valuation and utilization sensitivity.

Exponent Inc (EXPO) Investment Analysis

1. Executive Summary

Exponent Inc operates as a leading engineering and scientific consulting firm, utilizing over ninety technical disciplines to resolve highly complex, safety-critical challenges [cite: 1, 2]. The company primarily generates revenue through time-and-materials contracts [cite: 3], billing clients for the specialized expertise of its consultants [cite: 3, 4]. These billable fees are typically derived from professional hourly rates applied to consultant hours [cite: 3, 4], alongside reimbursable expenses incurred during project execution [cite: 5, 6]. The organization operates and measures its financial performance through two core business segments: the Engineering and Other Scientific segment, which represents approximately 85% of revenues before reimbursements [cite: 5], and the Environmental and Health segment, which contributes the remaining 15% [cite: 3, 7]. Geographically, the firm operates out of thirty offices located across North America, Asia, and Europe [cite: 1, 8], enabling seamless delivery to both domestic and international clients [cite: 1, 9].

The products and services Exponent provides are highly specialized, spanning forensic failure investigations, accident reconstruction, product safety evaluations, biomechanics modeling, human factors analysis, and chemical hazard exposure assessments [cite: 10, 11]. Primary customer types include major multinational corporations, law firms preparing for complex multi-district litigation, insurance carriers evaluating catastrophic claims, and government or public-sector bodies [cite: 1, 12]. These clients operate in high-risk end markets such as technology (particularly consumer electronics and AI systems) [cite: 4, 10], transportation (autonomous vehicles and battery safety) [cite: 2, 10], utilities (grid integrity and wildfire risk management) [cite: 2, 10], and life sciences (medical device safety and clinical validation) [cite: 2, 4]. Clients choose Exponent over alternative consulting options due to its unrivaled scientific credibility, a massive roster of over 650 PhD-level professionals [cite: 1, 2], advanced specialized laboratory facilities such as the Phoenix Test & Engineering Center [cite: 2, 13], and a database of historical failure analysis that cannot be replicated by generalist consultancies [cite: 1, 8].

Operating Segment	Net Revenue Share [cite: 3, 5]	Core Service Applications [cite: 2, 10, 11]	Primary End Markets [cite: 2, 10, 14]
Engineering and Other Scientific	~85%	Failure analysis, biomechanics, civil/materials engineering, hardware safety, human factors	Technology, Transportation, Utilities, Medical Devices
Environmental and Health	~15%	EcoSciences, chemical registration, environmental modeling, food safety, exposure health	Chemical, Agriculture, Industrial Manufacturing, Government

2. Business Drivers & Strategic Overview

Exponent's underlying economic engine is driven by three main operational factors: professional headcount, average billable consultant utilization rates, and negotiated hourly billing rates [cite: 3, 4, 15]. Headcount growth functions as the primary expander of long-term operational capacity [cite: 16]. The firm consistently pursues selective, disciplined hiring in high-demand technical fields, targeting an annual technical full-time equivalent headcount growth rate of approximately 4% to 5% [cite: 12, 15, 17]. Utilization rates—representing the percentage of technical hours billed directly to clients—tend to stabilize between 72% and 76% depending on economic conditions and seasonal holiday placements [cite: 15, 18, 19]. Finally, the firm maintains strong pricing power, implementing steady annual increases in hourly billing rates that allow for positive net revenue expansion even during periods of volume contraction [cite: 3].

A key growth initiative is the strategic transition to proactive lifecycle consulting [cite: 12]. Historically, Exponent gained prominence through reactive, litigation-driven failure analysis and accident reconstruction [cite: 10, 20]. While reactive engagements remain a highly lucrative, defensive base [cite: 4], the firm is aggressively expanding into proactive consulting early in the product design phase [cite: 12]. In the technology sector, this involves supporting clients with human factors and user experience research during the development of novel consumer electronics and digital health systems [cite: 10]. In transportation and utility end markets, Exponent provides proactive safety modeling, asset integrity assessments, and automated driving risk frameworks [cite: 2, 10, 21]. The rapid proliferation and integration of artificial intelligence into physical hardware and safety-critical infrastructure acts as a primary catalyst for this shift [cite: 6, 10]. Because AI models face real-world physical edge cases and unexpected hardware-software-human interactions [cite: 10], corporate clients require deep empirical engineering assessments to mitigate catastrophic real-world liabilities [cite: 8, 10].

The company's competitive advantage is supported by several protective moats:

• Significant Brand Equity: Exponent acts as the premier "gold standard" in legal and regulatory venues [cite: 22]. Its reputation for scientific objectivity and rigorous methodology acts as a reliable shield for corporations facing intense public scrutiny or multi-billion-dollar legal disputes [cite: 1, 22, 23].
• High Switching Costs: Once engaged in a complex multi-year lawsuit, regulatory submission, or product recall, a client cannot easily replace Exponent without experiencing severe delays, cost duplications, and legal risks [cite: 12, 22].
• Scale and Talent Barriers: Boutique consulting operations lack the multidisciplinary breadth required to solve complex modern engineering failures [cite: 1, 2]. Uniting ninety disciplines and hundreds of PhDs under a single integrated global platform creates a scale barrier that competitors cannot easily duplicate [cite: 1, 2].
• Minimal Network Effects: The industry does not exhibit structural network effects, as consulting engagements are delivered as localized, bespoke problem-solving services [cite: 12, 22].

Exponent's total addressable market is expanding, driven by grid modernization, utility load growth, automated transit regulation, and emerging chemicals and health hazards [cite: 2, 10, 20, 24]. The competitive landscape consists of general professional services organizations, including FTI Consulting, CRA International, and Huron Consulting Group [cite: 25], alongside specialized environmental engineers such as Tetra Tech [cite: 26]. Exponent is uniquely positioned relative to these peers; it focuses on deep, PhD-level physical science and engineering rather than financial restructuring, economic consulting, or general management consulting [cite: 22, 25].

Financially, this differentiation manifests in Exponent’s high operating margins of approximately 19% to 26% and a superior return on invested capital of 32.6%, which significantly outperforms peers like FTI Consulting [cite: 7, 22]. The firm appears to be holding and gradually expanding its market share in critical, high-margin proactive technology and grid infrastructure safety niches [cite: 4, 10].

3. Financial Performance & Valuation

Exponent announced its latest quarterly financial results for the first quarter of fiscal year 2026 on April 30, 2026, covering the thirteen-week period ended April 3, 2026 [cite: 5, 6]. During the quarter, the firm delivered double-digit top-line growth and expanded its operating profitability [cite: 27].

Total revenues grew 14.3% to $166.303 million, up from $145.507 million in the first quarter of fiscal year 2025 [cite: 5, 7]. Revenues before reimbursements (net revenues) grew 10.5% to $151.817 million, compared to $137.437 million in the prior year quarter [cite: 4, 5].

GAAP net income for the quarter increased 11.0% to $29.569 million, or $0.59 per diluted share, representing a solid increase compared to net income of $26.650 million, or $0.52 per diluted share, in Q1 2025 [cite: 5, 6].

Metric	Q1 FY2026 [cite: 6, 7]	Q1 FY2025 [cite: 6, 7]	Analyst Consensus [cite: 4, 7]	Surprise / Performance [cite: 4, 7]
Total Revenues	\$166.30M	\$145.51M	\$149.53M	+11.2% (Beat)
Net Revenues	\$151.82M	\$137.44M	\$144.47M	+5.1% (Beat)
Diluted EPS	\$0.59	\$0.52	\$0.57	+3.5% (Beat)
EBITDA	\$43.10M	\$37.50M	—	+14.9% (YoY Increase)

The first quarter performance was driven by an increase in billable hours, which grew 6% year-over-year to approximately 399,000 hours [cite: 4, 15]. Average technical full-time equivalent employees grew 5% to 1,013 [cite: 4, 15]. Consultant utilization rose to 76%, up from 75% in the first quarter of fiscal year 2025 [cite: 15].

Segment performance was led by the Engineering and Other Scientific segment, which generated $129.0 million of revenues before reimbursements (representing 85% of total net revenues) and grew 12% year-over-year [cite: 5, 6, 27]. This segment benefited from a strong recovery in AI-integrated consumer electronics and robust failure analysis demand across critical utility energy facilities [cite: 4].

Operating income was $41.379 million, down slightly from $44.432 million in Q1 2025, primarily due to an increase in compensation and related expenses, which rose to $91.409 million from $75.903 million [cite: 5, 6]. However, net profitability was aided by positive shifts in miscellaneous non-operating income, which recorded a net expense of $0.758 million compared to a significant net loss of $9.386 million in the prior year quarter [cite: 5, 6].

Exponent maintained its full-year guidance for fiscal year 2026 [cite: 5, 6]. The company anticipates revenues before reimbursements to grow in the high-single digits, and EBITDA to represent 27.6% to 28.1% of revenues before reimbursements [cite: 5, 6, 27].

For the second quarter of fiscal year 2026, Exponent projected net revenues to grow in the high-single digits and EBITDA to represent 27.0% to 27.8% of revenues before reimbursements [cite: 27].

During the earnings conference call, management noted that the accelerating integration of complex automated physical components, human factor expectations, and AI interfaces into consumer and utility products is creating steady demand for Exponent's specialized scientific expertise [cite: 6].

The immediate stock market reaction post-earnings was positive, with the stock rising 1.07% in aftermarket trading to close at $66.95 [cite: 4]. However, the earnings beat did not ignite a sustained upward rally due to ongoing valuation concerns [cite: 7]. In May 2026, several equity research analysts revised their price targets downward to reflect high forward valuation multiples [cite: 7]. Specifically, UBS maintained its Neutral stance but lowered its price target from $85 to $75, while JP Morgan cut its target from $95 to $80 [cite: 7]. Analysts highlighted that the stock’s forward price-to-earnings ratio of 31.8x leaves little room for execution errors, as much of the expected positive fundamental news appears fully priced into the shares [cite: 7].

To evaluate the stock's long-term value, investors must look beyond simple near-term multiples and assess the financial metrics that support its structural compounding profile [cite: 2]. Over the past five fiscal years (2020–2025), Exponent's total revenues grew at a CAGR of 7.8% [cite: 28], while its net revenues grew at a CAGR of approximately 5.4% [cite: 17, 29].

The company's asset-light business model requires minimal capital expenditures, which averaged approximately $5.5 million in fiscal year 2025 (less than 1% of total revenues) [cite: 3, 28]. Consequently, the firm converts a high percentage of operating cash flows directly into free cash flow [cite: 2, 7].

This consistent cash generation supports a strong capital return program [cite: 1, 2]. In Q1 2026, the firm paid $16.6 million in quarterly dividends (representing a dividend increase from $0.30 to $0.31 per share) [cite: 1, 5] and deployed $78.8 million to repurchase outstanding shares [cite: 5, 6].

Furthermore, the board raised the share buyback authorization by an additional $50 million, highlighting management’s focus on returning capital to shareholders [cite: 5, 6].

4. Risk Assessment & Macroeconomic Considerations

Exponent's premium valuation and specialized operational model are exposed to several risks that could impact its performance:

• Company-Specific Execution Risks: Exponent’s primary bottleneck to growth is the recruitment, development, and retention of highly credentialed PhD-level professionals [cite: 16]. If the firm experiences a rise in employee turnover or fails to attract top-tier scientific talent, its long-term billable capacity will be constrained [cite: 16, 30]. Furthermore, recent executive changes, including John Pye's promotion to President and Eric Anderson's transition to CFO, introduce execution risk as the new leadership team establishes its direction [cite: 6, 7, 13].
• Competitive Risks: While Exponent possesses significant expertise, it faces competition from specialized engineering boutiques and generalist professional consulting firms [cite: 31]. Aggressive price competition or talent poaching from well-capitalized consulting groups could pressure billing rates or utilization [cite: 1, 31, 32].
• Customer Concentration or Demand Risks: The company is exposed to corporate spending trends in cyclical sectors, particularly consumer products, technology, and transportation [cite: 3]. A sharp reduction in corporate R&D budgets or a pause in client product lifecycles would directly impact utilization rates [cite: 18, 19].
• Regulatory or Legal Risks: Exponent’s brand equity relies heavily on its scientific objectivity and credibility in courtrooms and regulatory proceedings [cite: 21, 22]. The business faces reputational risk from critics who claim its findings skew toward corporate defense needs [cite: 23]. Any systematic ruling that disqualifies Exponent's forensic evidence in high-profile litigation would severely damage its brand value [cite: 22].
• Balance Sheet / Capital Allocation Risks: Although the firm has zero debt [cite: 19, 30], deploying large sums to repurchase shares at high multiples (such as a forward P/E exceeding 31x) poses capital allocation risks if the expected long-term growth fails to materialize [cite: 5, 6, 7].
• Industry Structure Risks: The strategic transition toward proactive consulting exposes the firm to more discretionary corporate budgets [cite: 12]. Unlike reactive litigation support, which is legally mandated and less sensitive to cost, proactive evaluations can be deferred by clients during cash-preservation cycles [cite: 12, 30].
• Macroeconomic Sensitivities: High interest rates and broader economic uncertainty can defer large-scale utility grid upgrades and automated vehicle capital projects, directly reducing associated safety and performance validation assignments [cite: 1, 2, 32].

To monitor the performance of the investment thesis, investors should distinguish between short-term noise, early warning signs, and structural damage:

• Temporary Operational Issues: Minor quarterly declines in utilization due to unfavorable holiday placement or project delays, which typically resolve over a full-year period [cite: 18, 19].
• Early Warning Signs: A consecutive decline in technical full-time equivalent headcount, multiple quarters of falling utilization below the 70% threshold, or a contraction in the EBITDA margin below 25% [cite: 18, 19].
• Damage to the Long-Term Thesis: A major legal precedent or regulatory exclusion that rejects Exponent’s scientific findings due to structural bias, which would permanently erode the company's brand equity and competitive position [cite: 22, 23].

5. 5-Year Scenario Analysis

This five-year scenario analysis projects Exponent's financial performance through fiscal year 2030, using the FY2025 net revenue base of $536.76 million and a diluted share count of 51.24 million as the starting points [cite: 17]. The current share price of $62.88 (as of July 17, 2026) is utilized as the baseline for returns [cite: 2].

Base Case (55% Probability)

The Base Case assumes that Exponent maintains its steady growth path, driven by utility grid modernization, electrified transport safety validation, and AI-integrated product testing [cite: 2, 10]. Net revenues are projected to grow at an 8.0% CAGR, reaching $788.68 million by Year 5.

The EBITDA margin is expected to remain stable at 28.0% [cite: 5, 6], while the GAAP net income margin normalizes at 19.5% [cite: 7, 28], yielding a projected net income of $153.79 million.

Due to continuous, cash-flow-funded share repurchases [cite: 5, 6], the diluted share count is expected to decrease at a 1.5% annual rate, falling to 46.50 million shares.

This generates a projected Year 5 EPS of:

$\text{EPS}_{\text{Base}} = \frac{\$153.79\text{ million}}{46.50\text{ million}} = \$3.31$

Applying a normalized P/E multiple of 28.0x (reflecting a slight contraction from current elevated levels due to broader market multiple stabilization) [cite: 7, 28], the implied future share price is $92.68. This yields a 5-year price return of 47.39% (8.07% annualized). When adding a projected average annual dividend yield of 2.2% [cite: 33], the total estimated return reaches approximately 58.4%.

High Case (25% Probability)

The High Case assumes that rapid growth in AI data center substations, grid complexity, and automated system liabilities accelerates demand for Exponent's services [cite: 10, 24, 34]. Net revenues are projected to grow at an 11.0% CAGR, reaching $904.48 million by Year 5.

Operating leverage expands the EBITDA margin to 29.5% [cite: 17, 29], while the net income margin rises to 21.0% [cite: 7, 28], resulting in a net income of $189.94 million.

Accelerated share buybacks reduce the diluted share count to 45.30 million shares (a 2.4% annual reduction).

This generates a projected Year 5 EPS of:

$\text{EPS}_{\text{High}} = \frac{\$189.94\text{ million}}{45.30\text{ million}} = \$4.19$

Applying a premium P/E multiple of 33.0x [cite: 7, 28], the implied future share price is $138.27. This results in a 5-year price return of 119.89% (17.07% annualized).

Low Case (20% Probability)

The Low Case assumes a sluggish economic environment where clients trim proactive R&D budgets [cite: 31] and utility upgrades slow down, limiting net revenue growth to a 4.0% CAGR, reaching $653.05 million by Year 5.

Reduced utilization compresses the EBITDA margin to 25.5% [cite: 18, 19], and the net income margin falls to 17.5%, resulting in a net income of $114.28 million.

Lower free cash flows reduce the pace of share buybacks, leaving the share count at 48.50 million shares.

This generates a projected Year 5 EPS of:

$\text{EPS}_{\text{Low}} = \frac{\$114.28\text{ million}}{48.50\text{ million}} = \$2.36$

Applying a compressed P/E multiple of 22.0x, the implied future share price is $51.92, resulting in a 5-year price return of -17.43% (-3.76% annualized).

Probability-Weighted Outlook

Summing the weighted outcomes (55% Base, 25% High, 20% Low) yields a probability-weighted future share price target of:

$\text{Weighted Price} = (0.55 \times \$92.68) + (0.25 \times \$138.27) + (0.20 \times \$51.92) = \$95.92$

This indicates a solid long-term upside potential of 52.54% from the current baseline price of $62.88 [cite: 2].

Scenario	Revenue in Year 5 (Net)	Margin / Earnings Assumption	Valuation Multiple Assumption	Current Share Price	Implied Future Share Price	5-Year Total Return	Annualized Return	Probability
High Case	\$904.48M	21.0% Net Margin / \$4.19 EPS	33.0x P/E Multiple	\$62.88	\$138.27	119.89%	17.07%	25.0%
Base Case	\$788.68M	19.5% Net Margin / \$3.31 EPS	28.0x P/E Multiple	\$62.88	\$92.68	47.39%	8.07%	55.0%
Low Case	\$653.05M	17.5% Net Margin / \$2.36 EPS	22.0x P/E Multiple	\$62.88	\$51.92	-17.43%	-3.76%	20.0%

ASYMMETRIC UPSIDE PROFILE

6. Qualitative Scorecard

Evaluating Exponent's fundamental business characteristics helps establish its long-term investment profile:

• Management Alignment (8/10): The executive compensation program is linked to long-term performance objectives, utilizing peer groups of professional service firms to avoid misaligned incentives [cite: 25]. Insider transactions are occasional and minor; for instance, the CEO's sale of $109,044 in stock represents a small fraction of overall holdings [cite: 35], confirming strong alignment with shareholders.
• Revenue Quality (9/10): Exponent displays high revenue quality, supported by long-term legal relationships and recurring proactive consulting programs with major utility and tech clients [cite: 30, 36]. It is insulated from short-term churn due to the essential nature of its failure investigations [cite: 10].
• Market Position (9/10): The company holds a leading position in scientific and failure analysis consulting [cite: 1, 2]. No major competitor has successfully matched its roster of 650+ PhDs across ninety disciplines [cite: 1, 2, 22].
• Growth Outlook (8/10): Tailwinds from AI-integrated products, advanced medical device regulation, and utility grid upgrades support solid medium-term growth [cite: 2, 4, 10].
• Financial Health (10/10): With zero debt, a current ratio of 3.15 [cite: 19], and $118.6 million in cash [cite: 5, 6], Exponent's financial health is exceptional.
• Business Viability (9/10): The risk of technological obsolescence is low [cite: 10]. Complex physical, biological, and legal problems require human scientific interpretation, meaning the business cannot be easily disrupted by automated software solutions [cite: 10].
• Capital Allocation (8/10): Exponent maintains a disciplined capital allocation strategy, balancing reinvestment in laboratories with regular dividend growth (recently raised to $0.31) [cite: 1, 13] and share buybacks [cite: 5, 6]. However, share repurchases executed at premium valuations represent a moderate risk [cite: 7].
• Analyst Sentiment (6/10): Analyst sentiment is mixed [cite: 7]. While the fundamental business model is respected, major firms revised their price targets downward in mid-2026 due to the stock's high forward P/E multiple [cite: 7].
• Profitability (10/10): The business achieves high operating margins and a superior ROIC (32.6%) compared to its peer group, demonstrating strong pricing power [cite: 22].
• Track Record (9/10): Over its fifty-year history, Exponent has established a strong record of shareholder value creation through disciplined hiring, operational execution, and consistent dividend growth [cite: 2, 16, 33].

Blended Score: 8.6 / 10.0

PREMIUM MOATED FRANCHISE

7. Conclusion & Investment Thesis

Exponent Inc represents a high-quality, defensively positioned professional services business with a robust competitive moat [cite: 2, 22, 37]. The firm's long-term success is anchored in its exceptional PhD-level talent, scientific objectivity, and proprietary failure database [cite: 1, 2, 8].

The primary catalysts for future expansion include:

• Proactive Grid Modernization and Electrification Advisory: High electricity load growth, driven by AI data centers and manufacturing, is creating demand for Exponent's asset-integrity and risk-mitigation services [cite: 10, 24, 34].
• Validation of AI and Automated Technologies: The physical limitations of automated systems under real-world conditions require rigorous scientific and human engineering evaluations, positioning Exponent well to capture proactive technology spending [cite: 10].
• Consistent Shareholder Returns: Disciplined cash conversion supports continuous dividend increases and opportunistic share repurchases [cite: 1, 5, 27].

However, the primary investment risk is valuation [cite: 7]. The stock's historically high P/E multiple implies that much of its near-term growth is already priced in, leaving the shares sensitive to minor utilization or margin fluctuations [cite: 7].

In conclusion, Exponent is an attractive long-term compounder, well-suited for investors seeking defensive exposure to advanced secular technology trends with minimal balance sheet risk [cite: 2, 30].

HIGH QUALITY COMPOUNDER

8. Technical Analysis, Price Action & Short-Term Outlook

As of mid-July 2026, Exponent's stock trades around $62.88, near its 52-week low of $63.25, reflecting broader market multiple adjustments and analyst price target reductions [cite: 2, 4]. The stock is trading below its 200-day moving average of $62.11 [cite: 38], with short-term moving averages and technical indicators signaling a consolidation phase [cite: 39, 40]. Tactically, the stock is expected to remain range-bound in the short term, with investor attention focused on the upcoming Q2 FY2026 earnings release on July 30, 2026, which will serve as the next directional catalyst [cite: 7, 13].

RANGEBOUND BEFORE CATALYST

---

1. Exponent Increases Quarterly Dividend Payment from $0.30 to $0.31 per Share for Q1 2026, https://investors.exponent.com/investors/news-events/news-details/2026/Exponent-Increases-Quarterly-Dividend-Payment-from-0-30-to-0-31-per-Share-for-Q1-2026/default.aspx
2. Exponent, Inc - Investors Driven by Scientific Excellence & Impact, https://investors.exponent.com/investors/overview/default.aspx
3. 10-K - SEC.gov, https://www.sec.gov/Archives/edgar/data/851520/000119312526082508/expo-20260102.htm
4. Earnings call transcript: Exponent Q1 2026 sees stock rise post-earnings - Investing.com, https://www.investing.com/news/transcripts/earnings-call-transcript-exponent-q1-2026-sees-stock-rise-postearnings-93CH-4651520
5. Exponent Reports First Quarter 2026 Financial Results - Stock Titan, https://www.stocktitan.net/news/EXPO/exponent-reports-first-quarter-2026-financial-w8lu9f71noms.html
6. Exponent Reports First Quarter 2026 Financial Results, https://investors.exponent.com/investors/news-events/news-details/2026/Exponent-Reports-First-Quarter-2026-Financial-Results/default.aspx
7. Exponent (EXPO) | Trefis, https://www.trefis.com/data/companies/EXPO
8. Hard Questions. Tough Challenges. Bring It. | Exponent The premier scientific and engineering consulting firm, https://www.exponent.com/
9. Exponent to Announce Second Quarter of Fiscal Year 2026 Results and Host Quarterly Conference Call on July 30, 2026 | Nasdaq, https://www.nasdaq.com/press-release/exponent-announce-second-quarter-fiscal-year-2026-results-and-host-quarterly
10. 2025 Annual Report, https://s202.q4cdn.com/138815758/files/doc_financials/2025/ar/Exponent-Bookmarked-Annual-Report.pdf
11. Form 10-K - SEC.gov, https://www.sec.gov/Archives/edgar/data/851520/000119312507049476/d10k.htm
12. Exponent Strategy and Business Model - Umbrex, https://umbrex.com/resources/company-profiles/exponent/
13. Exponent to Announce Second Quarter of Fiscal Year 2026 Results and Host Quarterly Conference Call on July 30, 2026 - Finviz, https://finviz.com/news/367113/exponent-to-announce-second-quarter-of-fiscal-year-2026-results-and-host-quarterly-conference-call-on-july-30-2026
14. EXPONENT INC (Form: 10-K, Received - EDGAR Online, https://content.edgar-online.com/ExternalLink/EDGAR/0001193125-09-036413.html?hash=92f067311275c1e6b05984c67d8410e7761ca2c1276243cab490bab77c798b2a&dest=dex1031_htm
15. Exponent EXPO Q1 2026 Earnings Call Transcript - The Motley Fool, https://www.fool.com/earnings/call-transcripts/2026/04/30/exponent-expo-q1-2026-earnings-call-transcript/
16. 2022 Annual Report, https://s202.q4cdn.com/138815758/files/doc_financials/2022/ar/Exponent-Annual-Report.pdf
17. Exponent Reports Fourth Quarter and Fiscal Year 2025 Financial Results, https://investors.exponent.com/investors/news-events/news-details/2026/Exponent-Reports-Fourth-Quarter-and-Fiscal-Year-2025-Financial-Results/default.aspx
18. Exponent, Inc. (EXPO) Q2 2025 Earnings Call Transcript | Seeking Alpha, https://seekingalpha.com/article/4807299-exponent-inc-expo-q2-2025-earnings-call-transcript
19. Earnings call transcript: Exponent Q2 2025 Revenue Rises, Stock Remains Stable, https://www.investing.com/news/transcripts/earnings-call-transcript-exponent-q2-2025-revenue-rises-stock-remains-stable-93CH-4288279
20. 2023 Annual Report, https://s202.q4cdn.com/138815758/files/doc_financials/2023/ar/EXPO-Annual-Report-2023.pdf
21. 2021 Annual Report, https://s202.q4cdn.com/138815758/files/doc_financials/2021/ar/exponent-2021-annual-report.pdf
22. Exponent, Inc. (EXPO) Competitive Analysis & Comparison (2026) - KoalaGains, https://koalagains.com/stocks/NASDAQ/EXPO/competition
23. Exponent, Inc. - Wikipedia, https://en.wikipedia.org/wiki/Exponent,_Inc.
24. FOR THE YEAR ENDED JANUARY 2, 2026 - SEC.gov, https://www.sec.gov/Archives/edgar/data/1370450/000110465926048632/wldn-20251231xars.pdf
25. DEF 14A - SEC.gov, https://www.sec.gov/Archives/edgar/data/851520/000119312526163945/expo-20260416.htm
26. Top Exponent Competitors and Alternatives - Craft.co, https://craft.co/exponent/competitors
27. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K - Cloudfront.net, https://d18rn0p25nwr6d.cloudfront.net/CIK-0000851520/247aa4d4-9c82-470c-935e-367a72e11035.pdf
28. Exponent Stock Price | EXPO Stock Quote, News, and History | Markets Insider, https://markets.businessinsider.com/stocks/expo-stock
29. Exponent Reports Fourth Quarter and Fiscal Year 2022 Financial Results - SEC.gov, https://www.sec.gov/Archives/edgar/data/851520/000117184323000631/exh_991.htm
30. Exponent Inc. (EXPO): A Closer Look at the Engineering Consulting Firm's Prospects - Tech Earnings Analysis - Gulf SQAS, https://gulfsqas.com/first-dry/Exponent-Inc-EXPO-A-Closer-Look-at-the-Engineering-Consulting-Firms-Prospects-29-13692
31. Earnings call transcript: Exponent Q4 2025 earnings beat expectations - Investing.com, https://www.investing.com/news/transcripts/earnings-call-transcript-exponent-q4-2025-earnings-beat-expectations-93CH-4489153
32. EdgarFiling - SEC.gov, https://www.sec.gov/Archives/edgar/data/851520/000117184325006835/exh_992.htm
33. Exponent (DB:EP5) - Earnings & Revenue Performance - Simply Wall St, https://simplywall.st/stocks/de/commercial-services/fra-ep5/exponent-shares/past
34. Exponent to Announce Second Quarter of Fiscal Year 2026 Results and Host Quarterly Conference Call on July 30, 2026 - Barchart.com, https://www.barchart.com/story/news/3214314/exponent-to-announce-second-quarter-of-fiscal-year-2026-results-and-host-quarterly-conference-call-on-july-30-2026
35. Exponent CEO Corrigan sells $109044 in EXPO common stock - Investing.com UK, https://uk.investing.com/news/stock-market-news/exponent-ceo-corrigan-sells-109044-in-expo-common-stock-93CH-4777041
36. Exponent, Inc. (EXPO): Assessing Portfolio Fit Amid Consulting Demand - Net Profit Margin, https://services.thebmc.co.uk/first-dry/Exponent-Inc-EXPO-Assessing-Portfolio-Fit-Amid-Consulting-Demand-31-15092
37. 2026 Investor Presentation, https://s202.q4cdn.com/138815758/files/doc_presentation/2026/EXPO-2026-IR-Presentation_Q1-2026_4-30-26.pdf
38. Expo Gas Containers Ltd Share Technical Analysis (EXPO) - Investing.com NG - Test -{{UPSIDE_OR_DOWNSIDE}} - {{DIVIDEND_YIELD}} - {{CURRENT_YEAR}}, https://ng.investing.com/equities/expo-gas-containers-bo-technical
39. Export Inv Share Technical Analysis (EXPO) - Investing.com NG - Test -{{UPSIDE_OR_DOWNSIDE}} - {{DIVIDEND_YIELD}} - {{CURRENT_YEAR}}, https://ng.investing.com/equities/export-inv-technical
40. EXPO Barchart Opinion for Exponent Stock, https://www.barchart.com/stocks/quotes/expo/opinion